Factors Associated With Infusion Reactions in Patients With Breast Cancer Receiving Trastuzumab.

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Trastuzumab (TRA) is a critical therapy for HER2-positive breast cancer.
• Infusion reactions (IR) are common with TRA, causing patient discomfort and increased healthcare costs.
• Premedication for TRA-induced IR is not consistently utilized despite reported efficacy.

Purpose of the Study:

• To identify factors associated with the occurrence of infusion reactions (IR) in breast cancer patients receiving trastuzumab (TRA).
• To analyze predictors of TRA-induced IR to improve patient management and treatment outcomes.

Main Methods:

• Retrospective study of 204 patients treated with TRA for breast cancer between September 2008 and June 2023.
• Analysis of factors influencing IR occurrence during TRA administration.
• Logistic regression analysis to determine significant associations.

Main Results:

• A total of 182 patients were included in the final analysis.
• The incidence of IR was 25.8% (47 out of 182 patients).
• Pertuzumab (PER) use, elevated alkaline phosphatase (ALP), and low high-density lipoprotein (HDL) cholesterol levels were significantly associated with IR.

Conclusions:

• Infusion reactions (IR) should be anticipated when combining pertuzumab (PER) with trastuzumab (TRA).
• Alkaline phosphatase (ALP) and HDL cholesterol levels may serve as predictive biomarkers for TRA-induced IR in breast cancer patients.
• Identifying patients at risk for IR can guide prophylactic strategies and optimize TRA therapy.